Breaking News Instant updates and real-time market news.

PCG

PG&E

$10.53 /

-0.355 (-3.26%)

17:10
02/26/21
02/26
17:10
02/26/21
17:10

PG&E files automatic mixed securities shelf

  • 26

    Jun

PCG PG&E
$10.53 /

-0.355 (-3.26%)

02/12/21 Mizuho
PG&E price target raised to $15 from $14 at Mizuho
01/06/21 Wells Fargo
Wells Fargo says buy CenterPoint Energy, sell FirstEnergy
01/06/21 Wells Fargo
PG&E downgraded to Underweight from Equal Weight at Wells Fargo
11/18/20 Barclays
PG&E price target raised to $14 from $13 at Barclays

TODAY'S FREE FLY STORIES

General news
U.S. trade price preview » 02:15
04/14/21
04/14
02:15
04/14/21
02:15
$ECON

Economic Data

/

+

U.S. trade price preview:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
    General news
    Asian Market Update: » 01:50
    04/14/21
    04/14
    01:50
    04/14/21
    01:50
    $ECON

    Economic Data

    /

    +

    Asian Market Update:…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
      Downgrade
      Organigram downgraded to Underperformer from Neutral at CIBC » 21:33
      04/13/21
      04/13
      21:33
      04/13/21
      21:33
      OGI

      Organigram

      $2.92 /

      +0.145 (+5.23%)

      CIBC analyst John Zamparo…

      CIBC analyst John Zamparo downgraded Organigram to Underperformer from Neutral with a C$3.25 price target.

      ShowHide Related Items >><<
      OGI Organigram
      $2.92 /

      +0.145 (+5.23%)

      OGI Organigram
      $2.92 /

      +0.145 (+5.23%)

      04/13/21 Alliance Global Partners
      Organigram price target lowered to C$3.75 from C$4 at Alliance Global Partners
      04/07/21 BMO Capital
      Organigram upgraded to Market Perform from Underperform at BMO Capital
      03/16/21 Stifel
      Organigram price target raised to C$6 from C$1.90 at Stifel
      03/15/21 BMO Capital
      Organigram price target raised to C$4 from C$2 at BMO Capital
      OGI Organigram
      $2.92 /

      +0.145 (+5.23%)

      OGI Organigram
      $2.92 /

      +0.145 (+5.23%)

      OGI Organigram
      $2.92 /

      +0.145 (+5.23%)

      OGI Organigram
      $2.92 /

      +0.145 (+5.23%)

      Hot Stocks
      Splunk CEO sells 15.5K shares of common stock » 20:28
      04/13/21
      04/13
      20:28
      04/13/21
      20:28
      SPLK

      Splunk

      $147.69 /

      +3.07 (+2.12%)

      In a regulatory filing,…

      In a regulatory filing, Splunk disclosed that its CEO Douglas Merritt sold 15,465 shares of common stock on April 12th in a total transaction size of $2.24M, reducing his stake by about 5%.

      ShowHide Related Items >><<
      SPLK Splunk
      $147.69 /

      +3.07 (+2.12%)

      SPLK Splunk
      $147.69 /

      +3.07 (+2.12%)

      04/08/21 BofA
      Splunk reinstated with a Buy at BofA
      04/08/21 BofA
      Splunk reinstated with a Buy at BofA
      04/05/21 Goldman Sachs
      Splunk chief growth officer hire a 'significant positive,' says Goldman Sachs
      03/15/21 Credit Suisse
      Splunk assumed with an Outperform at Credit Suisse
      SPLK Splunk
      $147.69 /

      +3.07 (+2.12%)

      SPLK Splunk
      $147.69 /

      +3.07 (+2.12%)

      SPLK Splunk
      $147.69 /

      +3.07 (+2.12%)

      SPLK Splunk
      $147.69 /

      +3.07 (+2.12%)

      Periodicals
      KKR, Brookfield Asset Management mulling bid for Toshiba, Bloomberg reports  20:22
      04/13/21
      04/13
      20:22
      04/13/21
      20:22
      TOSBF

      Toshiba, also use TOSYY

      $44.83 /

      +4.41 (+10.91%)

      , TOSYY

      Toshiba

      $23.28 /

      +2.43 (+11.65%)

      , KKR

      KKR

      $52.04 /

      +0.025 (+0.05%)

      , BAM

      Brookfield

      $45.52 /

      -0.44 (-0.96%)

       
      ShowHide Related Items >><<
      TOSYY Toshiba
      $23.28 /

      +2.43 (+11.65%)

      KKR KKR
      $52.04 /

      +0.025 (+0.05%)

      BAM Brookfield
      $45.52 /

      -0.44 (-0.96%)

      TOSBF Toshiba, also use TOSYY
      $44.83 /

      +4.41 (+10.91%)

      04/22/20 UBS
      Toshiba downgraded to Neutral from Buy at UBS
      TOSYY Toshiba
      $23.28 /

      +2.43 (+11.65%)

      03/19/21 SMBC Nikko
      Toshiba upgraded to Outperform from Neutral at SMBC Nikko
      02/19/21 Citi
      Toshiba resumed with a Neutral at Citi
      KKR KKR
      $52.04 /

      +0.025 (+0.05%)

      04/09/21 DA Davidson
      Box price target lowered to $22 from $25 at DA Davidson
      04/09/21 William Blair
      KKR investment 'strong vote of confidence' in Box, says William Blair
      04/09/21 William Blair
      KKR investment 'strong vote of confidence' in Box, says William Blair
      04/07/21 Seaport Global
      Seaport downgrades Sempra Energy to Neutral after 'good, not great' SIP deal
      BAM Brookfield
      $45.52 /

      -0.44 (-0.96%)

      04/09/21 Deutsche Bank
      Brookfield price target raised to $45 from $43 at Deutsche Bank
      04/01/21 Evercore ISI
      Brookfield Property downgraded to In Line from Outperform at Evercore ISI
      03/31/21
      Fly Intel: Top five analyst downgrades
      03/31/21 Credit Suisse
      Brookfield downgraded to Neutral from Outperform at Credit Suisse
      KKR KKR
      $52.04 /

      +0.025 (+0.05%)

      BAM Brookfield
      $45.52 /

      -0.44 (-0.96%)

      • 11
        Nov
      TOSYY Toshiba
      $23.28 /

      +2.43 (+11.65%)

      TOSBF Toshiba, also use TOSYY
      $44.83 /

      +4.41 (+10.91%)

      KKR KKR
      $52.04 /

      +0.025 (+0.05%)

      BAM Brookfield
      $45.52 /

      -0.44 (-0.96%)

      TOSYY Toshiba
      $23.28 /

      +2.43 (+11.65%)

      KKR KKR
      $52.04 /

      +0.025 (+0.05%)

      BAM Brookfield
      $45.52 /

      -0.44 (-0.96%)

      Earnings
      Steel Partners reports Q4 adjusted EBITDA $67.1M vs. $46.6M last year » 20:12
      04/13/21
      04/13
      20:12
      04/13/21
      20:12
      SPLP

      Steel Partners

      $14.35 /

      + (+0.00%)

      Reports Q4 revenue…

      Reports Q4 revenue $338.7M vs. $346.7M last year. Executive Chairman Warren Lichtenstein: "We were able to respond to the pandemic and economic volatility by reducing costs, improving our operational performance, and increasing our financial flexibility, which led to increased EBITDA and cash flow despite reduced revenue in 2020."

      ShowHide Related Items >><<
      SPLP Steel Partners
      $14.35 /

      + (+0.00%)

      SPLP Steel Partners
      $14.35 /

      + (+0.00%)

      SPLP Steel Partners
      $14.35 /

      + (+0.00%)

      Initiation
      Retail Opportunity reinstated with an Outperform at Baird » 20:06
      04/13/21
      04/13
      20:06
      04/13/21
      20:06
      ROIC

      Retail Opportunity

      $16.49 /

      +0.085 (+0.52%)

      Baird analyst Wesley…

      Baird analyst Wesley Golladay reinstated coverage of Retail Opportunity with an Outperform rating and $18 price target.

      ShowHide Related Items >><<
      ROIC Retail Opportunity
      $16.49 /

      +0.085 (+0.52%)

      ROIC Retail Opportunity
      $16.49 /

      +0.085 (+0.52%)

      02/24/21 DA Davidson
      Retail Opportunity price target raised to $18 from $12 at DA Davidson
      01/19/21 BofA
      Retail Opportunity double-upgraded to Buy from Underperform at BofA
      01/19/21 BofA
      Retail Opportunity upgraded to Buy from Underperform at BofA
      12/14/20 KeyBanc
      Retail Opportunity downgraded to Sector Weight from Overweight at KeyBanc
      ROIC Retail Opportunity
      $16.49 /

      +0.085 (+0.52%)

      Initiation
      RPT Realty reinstated with a Neutral at Baird » 20:06
      04/13/21
      04/13
      20:06
      04/13/21
      20:06
      RPT

      RPT Realty

      $11.83 /

      +0.025 (+0.21%)

      Baird analyst Wesley…

      Baird analyst Wesley Golladay reinstated coverage of RPT Realty with a Neutral rating and $12 price target.

      ShowHide Related Items >><<
      RPT RPT Realty
      $11.83 /

      +0.025 (+0.21%)

      RPT RPT Realty
      $11.83 /

      +0.025 (+0.21%)

      01/13/21 Jefferies
      Jefferies upgrades 'overlooked' RPT Realty to Buy
      01/13/21 Jefferies
      RPT Realty upgraded to Buy from Hold at Jefferies
      12/21/20 JPMorgan
      JPMorgan changes ratings in REIT, Real Estate Services sectors into 2021
      12/21/20 JPMorgan
      RPT Realty upgraded to Neutral from Underweight at JPMorgan
      RPT RPT Realty
      $11.83 /

      +0.025 (+0.21%)

      Initiation
      Retail Properties of America reinstated with a Neutral at Baird » 20:04
      04/13/21
      04/13
      20:04
      04/13/21
      20:04
      RPAI

      Retail Properties of America

      $10.90 /

      -0.005 (-0.05%)

      Baird analyst Wesley…

      Baird analyst Wesley Golladay reinstated coverage of Retail Properties of America with a Neutral rating and $12 price target.

      ShowHide Related Items >><<
      RPAI Retail Properties of America
      $10.90 /

      -0.005 (-0.05%)

      RPAI Retail Properties of America
      $10.90 /

      -0.005 (-0.05%)

      03/04/21
      Fly Intel: Top five analyst downgrades
      03/04/21 KeyBanc
      Retail Properties of America downgraded to Sector Weight at KeyBanc
      03/04/21 KeyBanc
      Retail Properties downgraded to Sector Weight from Overweight at KeyBanc
      12/15/20 Citi
      Retail Properties of America price target raised to $9.50 from $7 at Citi
      RPAI Retail Properties of America
      $10.90 /

      -0.005 (-0.05%)

      Initiation
      Regency Centers reinstated with a Neutral at Baird » 20:04
      04/13/21
      04/13
      20:04
      04/13/21
      20:04
      REG

      Regency Centers

      $59.24 /

      +0.84 (+1.44%)

      Baird analyst Wesley…

      Baird analyst Wesley Golladay reinstated coverage of Regency Centers with a Neutral rating.

      ShowHide Related Items >><<
      REG Regency Centers
      $59.24 /

      +0.84 (+1.44%)

      REG Regency Centers
      $59.24 /

      +0.84 (+1.44%)

      03/31/21 Truist
      Regency Centers price target raised to $57 from $50 at Truist
      03/16/21 Wells Fargo
      Regency Centers price target raised to $63 from $52 at Wells Fargo
      03/04/21 Argus
      Regency Centers downgraded to Hold from Buy at Argus
      03/04/21 Argus
      Regency Centers downgraded to Hold from Buy at Argus
      REG Regency Centers
      $59.24 /

      +0.84 (+1.44%)

      REG Regency Centers
      $59.24 /

      +0.84 (+1.44%)

      Initiation
      Kimco Realty reinstated with an Outperform at Baird » 20:02
      04/13/21
      04/13
      20:02
      04/13/21
      20:02
      KIM

      Kimco Realty

      $19.68 /

      +0.22 (+1.13%)

      Baird analyst Wesley…

      Baird analyst Wesley Golladay reinstated coverage of Kimco Realty with an Outperform rating and $21 price target.

      ShowHide Related Items >><<
      KIM Kimco Realty
      $19.68 /

      +0.22 (+1.13%)

      KIM Kimco Realty
      $19.68 /

      +0.22 (+1.13%)

      03/05/21 Truist
      Kimco Realty price target raised to $20 from $18 at Truist
      02/12/21 Mizuho
      Kimco Realty price target raised to $20 from $17 at Mizuho
      01/11/21 Mizuho
      Kimco Realty upgraded to Buy from Neutral at Mizuho
      KIM Kimco Realty
      $19.68 /

      +0.22 (+1.13%)

      KIM Kimco Realty
      $19.68 /

      +0.22 (+1.13%)

      Initiation
      Weingarten Realty reinstated with an Outperform at Baird » 20:01
      04/13/21
      04/13
      20:01
      04/13/21
      20:01
      WRI

      Weingarten Realty

      $27.49 /

      +0.38 (+1.40%)

      Baird analyst Wesley…

      Baird analyst Wesley Golladay reinstated coverage of Weingarten Realty with an Outperform rating and $29 price target.

      ShowHide Related Items >><<
      WRI Weingarten Realty
      $27.49 /

      +0.38 (+1.40%)

      WRI Weingarten Realty
      $27.49 /

      +0.38 (+1.40%)

      03/09/21 BTIG
      Weingarten Realty price target raised to $28 from $25 at BTIG
      03/05/21 Truist
      Weingarten Realty price target raised to $28 from $24 at Truist
      01/28/21 Scotiabank
      Weingarten Realty upgraded to Outperform at Scotiabank on 'Sunbelt preference'
      01/28/21 Scotiabank
      Weingarten Realty upgraded to Outperform from Sector Perform at Scotiabank
      WRI Weingarten Realty
      $27.49 /

      +0.38 (+1.40%)

      Downgrade
      FLSmidth double-downgraded to Sell from Buy at Goldman Sachs » 19:59
      04/13/21
      04/13
      19:59
      04/13/21
      19:59
      FLIDY

      FLSmidth

      $3.74 /

      -0.11 (-2.86%)

      Goldman Sachs analyst…

      Goldman Sachs analyst Hameed Awan downgraded FLSmidth to Sell from Buy with a DKK 208 price target. The analyst says he is broadly positive on underlying trends in mining equipment, but FLSmidth's exposure to late-cycle spending means it will see a cyclical upswing later than some industry peers. Awan adds that he sees continued structural challenges in Cement given significant overcapacity and pricing pressure.

      ShowHide Related Items >><<
      FLIDY FLSmidth
      $3.74 /

      -0.11 (-2.86%)

      02/19/21 RBC Capital
      FLSmidth price target lowered to DKK 255 from DKK 270 at RBC Capital
      02/11/21 Morgan Stanley
      FLSmidth price target lowered to DKK 190 from DKK 200 at Morgan Stanley
      12/08/20 Nordea
      FLSmidth upgraded to Buy from Hold at Nordea
      12/07/20 JPMorgan
      FLSmidth price target raised to DKK 245 from DKK 230 at JPMorgan
      Initiation
      Epiroc initiated with a Buy at Goldman Sachs » 19:55
      04/13/21
      04/13
      19:55
      04/13/21
      19:55
      EPOKY

      Epiroc

      $23.87 /

      +0.06 (+0.25%)

      Goldman Sachs analyst…

      Goldman Sachs analyst Hameed Awan initiated coverage of Epiroc with a Buy rating and SEK 235 price target. The analyst is positive on the company's position as a premium player in the most attractive segment of the mining equipment market, along with its early cycle positioning with exposure to upstream and early-cycle mining equipment spending. Awan further cites the longer term industry shift towards underground mining where Epiroc holds strong share with a long track record.

      ShowHide Related Items >><<
      EPOKY Epiroc
      $23.87 /

      +0.06 (+0.25%)

      EPOKY Epiroc
      $23.87 /

      +0.06 (+0.25%)

      04/13/21 UBS
      Epiroc price target raised to SEK 200 from SEK 159 at UBS
      04/13/21 Pareto
      Epiroc downgraded to Sell from Hold at Pareto
      04/12/21 Societe Generale
      Epiroc downgraded to Hold on valuation at Societe Generale
      04/12/21 Societe Generale
      Epiroc downgraded to Hold from Buy at Societe Generale
      Initiation
      Metso Outotec reinstated with a Neutral at Goldman Sachs » 19:53
      04/13/21
      04/13
      19:53
      04/13/21
      19:53
      OUKPY

      Metso Outotec

      $5.66 /

      +0.04 (+0.71%)

      Goldman Sachs analyst…

      Goldman Sachs analyst Hameed Awan reinstated coverage of Metso Outotec with a Neutral rating and EUR 9.8 price target. The company's mid-term growth and returns trajectory is reflected in the current shares, even though the combined entity has executed strongly on its EUR120M cost synergies target following the merger of Metso and Outotec merger in June 2020, the analyst tells investors in a research note.

      ShowHide Related Items >><<
      OUKPY Metso Outotec
      $5.66 /

      +0.04 (+0.71%)

      04/12/21 Societe Generale
      Metso Outotec price target raised to EUR 11 from EUR 8.40 at Societe Generale
      02/19/21 Credit Suisse
      Metso Outotec price target raised to EUR 10.50 from EUR 9.40 at Credit Suisse
      02/17/21 UBS
      Metso Outotec price target raised to EUR 10.4 from EUR 10 at UBS
      02/17/21 Morgan Stanley
      Metso Outotec price target raised to EUR 9.60 from EUR 9.30 at Morgan Stanley
      Upgrade
      JFrog upgraded to Hold from Sell at Summit Insights » 19:06
      04/13/21
      04/13
      19:06
      04/13/21
      19:06
      FROG

      JFrog

      $51.99 /

      +0.68 (+1.33%)

      Summit Insights analyst…

      Summit Insights analyst Srini Nandury upgraded JFrog to Hold from Sell with a $50 price target.

      ShowHide Related Items >><<
      FROG JFrog
      $51.99 /

      +0.68 (+1.33%)

      FROG JFrog
      $51.99 /

      +0.68 (+1.33%)

      01/05/21 Piper Sandler
      JFrog price target lowered to $65 from $76 at Piper Sandler
      11/05/20 Stifel
      JFrog reported 'strong first print as a public company,' says Stifel
      10/26/20 Stifel
      SAP news impact may be company-specific for software sector, says Stifel
      10/12/20 JPMorgan
      JFrog initiated with an Overweight at JPMorgan
      FROG JFrog
      $51.99 /

      +0.68 (+1.33%)

      • 16
        Sep
      FROG JFrog
      $51.99 /

      +0.68 (+1.33%)

      FROG JFrog
      $51.99 /

      +0.68 (+1.33%)

      FROG JFrog
      $51.99 /

      +0.68 (+1.33%)

      Hot Stocks
      Galectin says Phase 1 belapectin data published in JITC » 19:03
      04/13/21
      04/13
      19:03
      04/13/21
      19:03
      GALT

      Galectin Therapeutics

      $2.17 /

      -0.105 (-4.62%)

      Galectin Therapeutics…

      Galectin Therapeutics announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer, the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab, a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma and head and neck squamous cell carcinoma. The paper, titled "Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor" describes results from an ongoing Phase 1 clinical study, a collaboration between Galectin Therapeutics and Providence Cancer Institute in Portland, Oregon. Following the recent publication of positive preclinical results that showed the inhibition of galectin-3 in combination with an agonist anti-OX40 monoclonal antibody reprograms the tumor microenvironment to favor anti-tumor activity, the current study tests the clinical hypothesis that galectin-3 blockade with belapectin in combination with pembrolizumab enhances tumor response for patients with advanced MM or HNSCC. In the study, as previously disclosed, an objective response was observed in 50% of MM and 33% of HNSCC patients. This compares favorably to published response rates on pembrolizumab alone. The authors noted that the combination was associated with fewer immune-mediated adverse events than anticipated with pembrolizumab alone. In addition, the analysis of patients' tumor tissue revealed reduced monocytic myeloid-derived suppressor cells and increased effector memory T-cell activation in responders compared with non-responders. Also, an increased baseline expression of galectin-3 positive tumor cells correlated with clinical response.

      ShowHide Related Items >><<
      GALT Galectin Therapeutics
      $2.17 /

      -0.105 (-4.62%)

      GALT Galectin Therapeutics
      $2.17 /

      -0.105 (-4.62%)

      Earnings
      Washington Federal reports Q2 EPS 56c, consensus 48c » 19:02
      04/13/21
      04/13
      19:02
      04/13/21
      19:02
      WAFD

      Washington Federal

      $30.81 /

      -0.64 (-2.03%)

      Reports Q2 NII $124.0M…

      Reports Q2 NII $124.0M vs. $109.4M last year and net interest margin 2.75% vs. 3.10% last year.

      ShowHide Related Items >><<
      WAFD Washington Federal
      $30.81 /

      -0.64 (-2.03%)

      WAFD Washington Federal
      $30.81 /

      -0.64 (-2.03%)

      WAFD Washington Federal
      $30.81 /

      -0.64 (-2.03%)

      Hot Stocks
      J&J pauses vaccinations in all COVID-19 vaccine clinical trials » 18:54
      04/13/21
      04/13
      18:54
      04/13/21
      18:54
      JNJ

      Johnson & Johnson

      $159.51 /

      -2.075 (-1.28%)

      In an updated statement,…

      In an updated statement, Johnson & Johnson said that it has made the decision to proactively delay the rollout of its COVID-19 vaccine in Europe and pause vaccinations in all Janssen COVID-19 vaccine clinical trials while it updates guidance for investigators and participants. "We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public," the company said. Reference Link

      ShowHide Related Items >><<
      JNJ Johnson & Johnson
      $159.51 /

      -2.075 (-1.28%)

      JNJ Johnson & Johnson
      $159.51 /

      -2.075 (-1.28%)

      04/13/21 Goldman Sachs
      J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
      04/13/21 Morgan Stanley
      Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
      04/13/21 JPMorgan
      Vaccine pause 'incremental negative' for J&J, says JPMorgan
      04/13/21 Piper Sandler
      Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
      JNJ Johnson & Johnson
      $159.51 /

      -2.075 (-1.28%)

      JNJ Johnson & Johnson
      $159.51 /

      -2.075 (-1.28%)

      JNJ Johnson & Johnson
      $159.51 /

      -2.075 (-1.28%)

      JNJ Johnson & Johnson
      $159.51 /

      -2.075 (-1.28%)

      Hot Stocks
      Televisa, Univision agree to combine content, production assets » 18:40
      04/13/21
      04/13
      18:40
      04/13/21
      18:40
      TV

      Televisa

      $10.12 /

      +0.09 (+0.90%)

      , SFTBY

      SoftBank

      $46.60 /

      +0.155 (+0.33%)

      Televisa (TV) and…

      Televisa (TV) and Univision announced that they have finalized a deal to combine their content and production assets. Televisa will receive $3B in cash and $1.5B in equity as part of the deal, and SoftBank (SFTBY) will invest $1B in the combined entity. Reference Link

      ShowHide Related Items >><<
      SFTBY SoftBank
      $46.60 /

      +0.155 (+0.33%)

      TV Televisa
      $10.12 /

      +0.09 (+0.90%)

      03/17/21 BBVA
      Televisa upgraded to Outperform from Market Perform at BBVA
      12/15/20 Morgan Stanley
      Televisa downgraded to Equal Weight following rally at Morgan Stanley
      12/15/20 Morgan Stanley
      Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
      05/12/20 Credit Suisse
      Televisa upgraded to Outperform from Neutral at Credit Suisse
      SFTBY SoftBank
      $46.60 /

      +0.155 (+0.33%)

      03/11/21 Jefferies
      SoftBank downgraded to Hold from Buy at Jefferies
      03/10/21 Morgan Stanley
      SoftBank resumed with an Equal Weight at Morgan Stanley
      11/27/20 Citi
      SoftBank price target raised to 11,000 yen from 10,200 yen at Citi
      09/18/20 Northland
      Combined Nvidia-ARM a long-term risk for AMD, Intel and Vicor, says Northland
      TV Televisa
      $10.12 /

      +0.09 (+0.90%)

      SFTBY SoftBank
      $46.60 /

      +0.155 (+0.33%)

      SFTBY SoftBank
      $46.60 /

      +0.155 (+0.33%)

      Periodicals
      Televisa to combine content, production assets with Univision, Bloomberg says » 18:37
      04/13/21
      04/13
      18:37
      04/13/21
      18:37
      TV

      Televisa

      $10.12 /

      +0.09 (+0.90%)

      Televisa will receive $3B…

      Televisa will receive $3B in cash and $1.5B in equity as part of the deal, according to Bloomberg.

      ShowHide Related Items >><<
      TV Televisa
      $10.12 /

      +0.09 (+0.90%)

      03/17/21 BBVA
      Televisa upgraded to Outperform from Market Perform at BBVA
      12/15/20 Morgan Stanley
      Televisa downgraded to Equal Weight following rally at Morgan Stanley
      12/15/20 Morgan Stanley
      Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
      05/12/20 Credit Suisse
      Televisa upgraded to Outperform from Neutral at Credit Suisse
      Upgrade
      Glencore upgraded to Buy from Neutral at Goldman Sachs » 18:35
      04/13/21
      04/13
      18:35
      04/13/21
      18:35
      GLNCY

      Glencore

      $7.85 /

      +0.03 (+0.38%)

      Goldman Sachs analyst…

      Goldman Sachs analyst Jack O'Brien upgraded Glencore to Buy from Neutral with a price target of 350 GBp, up from 290 GBp. The company is the biggest beneficiary of copper's path to $15,000 per ton among industrial miners, the analyst tells investors in a research note, stating that Glencore is the 2nd largest producer of copper globally. O'Brien adds that Glencore's commodity basket, including copper, zinc, nickel, cobalt, is "best placed" vs. peers with regard to the transition to renewables.

      ShowHide Related Items >><<
      GLNCY Glencore
      $7.85 /

      +0.03 (+0.38%)

      GLNCY Glencore
      $7.85 /

      +0.03 (+0.38%)

      04/12/21 Deutsche Bank
      Glencore price target raised to 400 GBp from 350 GBp at Deutsche Bank
      03/24/21 Morgan Stanley
      Glencore price target raised to 307 GBp from 274 GBp at Morgan Stanley
      03/05/21 JPMorgan
      Glencore price target raised to 360 GBp from 350 GBp at JPMorgan
      03/04/21 UBS
      Glencore price target raised to 330 GBp from 320 GBp at UBS
      GLNCY Glencore
      $7.85 /

      +0.03 (+0.38%)

      Periodicals
      Judge says Juul must face new racketeering allegations, Bloomberg says » 18:24
      04/13/21
      04/13
      18:24
      04/13/21
      18:24
      MO

      Altria Group

      $51.16 /

      -0.59 (-1.14%)

      Juul Labs, which is 35%…

      Juul Labs, which is 35% owned by Altria, will have to face new racketeering claims accusing the vaping company of deliberately targeting teenagers, as litigation centers on the individual founders and directors of the company, Bloomberg's Joel Rosenblatt reports. A federal judge in San Francisco said that most of the allegations brought by consumers, local governments, and school district against Juul and Altria under the Racketeer Influenced and Corrupt Organizations Act can proceed, the author notes. Reference Link

      ShowHide Related Items >><<
      MO Altria Group
      $51.16 /

      -0.59 (-1.14%)

      MO Altria Group
      $51.16 /

      -0.59 (-1.14%)

      03/26/21
      Fly Intel: Top five analyst upgrades
      03/26/21 Jefferies
      Altria Group upgraded to Buy from Hold at Jefferies
      03/19/21 Deutsche Bank
      Altria Group price target raised to $54 from $52 at Deutsche Bank
      03/16/21
      Fly Intel: Top five analyst downgrades
      MO Altria Group
      $51.16 /

      -0.59 (-1.14%)

      MO Altria Group
      $51.16 /

      -0.59 (-1.14%)

      MO Altria Group
      $51.16 /

      -0.59 (-1.14%)

      MO Altria Group
      $51.16 /

      -0.59 (-1.14%)

      Hot Stocks
      New Gold reports Q1 gold equivalent production 96,026 ounces » 18:21
      04/13/21
      04/13
      18:21
      04/13/21
      18:21
      NGD

      New Gold

      $1.82 /

      + (+0.00%)

      Reports Q1 gold…

      Reports Q1 gold production 66,650 ounces. Reports Q1 copper production 13.8 Mlbs. "During the quarter, the Rainy River Mine delivered to plan. Waste stripping was strategically prioritized during the winter months, which will set the mine up for higher grades and a stronger production profile in the second half of the year. The New Afton Mine continues to safely and sequentially ramp-up operations and we look forward to initiating ore extraction from the B3 zone. I am very proud of the progress the team has made at New Afton, and coupled with the execution at Rainy River, we remain on-track to achieve our annual guidance estimates," stated Renaud Adams, President & CEO. "Late last year, we re-launched exploration drilling programs at both operations after an extended period of inactivity. We are encouraged by the early-stage results to date."

      ShowHide Related Items >><<
      NGD New Gold
      $1.82 /

      + (+0.00%)

      NGD New Gold
      $1.82 /

      + (+0.00%)

      02/22/21 Canaccord
      New Gold price target lowered to C$2.75 from C$3.75 at Canaccord
      02/11/21 National Bank
      New Gold price target lowered to C$4 from C$4.25 at National Bank
      02/03/21 CIBC
      New Gold downgraded to Neutral after mine fatality at CIBC
      02/02/21 CIBC
      New Gold downgraded to Neutral from Outperformer at CIBC
      NGD New Gold
      $1.82 /

      + (+0.00%)

      On The Fly
      Fly Intel: After-Hours Movers » 18:19
      04/13/21
      04/13
      18:19
      04/13/21
      18:19
      SAP

      SAP

      $134.51 /

      +2.08 (+1.57%)

      , FLXN

      Flexion

      $9.37 /

      +1.05 (+12.62%)

      , BRKR

      Bruker

      $68.97 /

      +1.43 (+2.12%)

      , TEAM

      Atlassian

      $242.24 /

      +11.72 (+5.08%)

      , PKI

      PerkinElmer

      $135.39 /

      +2.695 (+2.03%)

      , MRNA

      Moderna

      $149.63 /

      +10.34 (+7.42%)

      , SEAC

      SeaChange

      $1.38 /

      -0.095 (-6.46%)

      , SFIX

      Stitch Fix

      $49.46 /

      -1.3 (-2.56%)

      , STSA

      Satsuma Pharmaceuticals

      $5.44 /

      +0.37 (+7.30%)

      Check out this evening's…

      ShowHide Related Items >><<
      TEAM Atlassian
      $242.24 /

      +11.72 (+5.08%)

      STSA Satsuma Pharmaceuticals
      $5.44 /

      +0.37 (+7.30%)

      SFIX Stitch Fix
      $49.46 /

      -1.3 (-2.56%)

      SEAC SeaChange
      $1.38 /

      -0.095 (-6.46%)

      SAP SAP
      $134.51 /

      +2.08 (+1.57%)

      PKI PerkinElmer
      $135.39 /

      +2.695 (+2.03%)

      MRNA Moderna
      $149.63 /

      +10.34 (+7.42%)

      FLXN Flexion
      $9.37 /

      +1.05 (+12.62%)

      BRKR Bruker
      $68.97 /

      +1.43 (+2.12%)

      SAP SAP
      $134.51 /

      +2.08 (+1.57%)

      04/09/21 Societe Generale
      SAP price target lowered to EUR 136 from EUR 138 at Societe Generale
      03/25/21 Credit Suisse
      SAP assumed with an Outperform at Credit Suisse
      03/12/21 JMP Securities
      Domo price target raised to $89 from $80 at JMP Securities
      03/10/21 Craig-Hallum
      Talend go-shop 'could spark interest,' says Craig-Hallum
      FLXN Flexion
      $9.37 /

      +1.05 (+12.62%)

      04/06/21 RBC Capital
      Flexion transferred with an Outperform at RBC Capital
      08/20/20 Goldman Sachs
      Flexion initiated with a Neutral at Goldman Sachs
      07/30/20 Oppenheimer
      Flexion initiated with an Outperform at Oppenheimer
      07/29/20
      Fly Intel: Top five analyst initiations
      BRKR Bruker
      $68.97 /

      +1.43 (+2.12%)

      02/17/21 Stifel
      Bruker price target raised to $65 from $48 at Stifel
      02/17/21 Citi
      Bruker price target raised to $65 from $57 at Citi
      02/05/21 Wells Fargo
      Bruker downgraded to Equal Weight with $55 target at Wells Fargo
      02/05/21 Wells Fargo
      Bruker downgraded to Equal Weight from Overweight at Wells Fargo
      TEAM Atlassian
      $242.24 /

      +11.72 (+5.08%)

      03/08/21 Morgan Stanley
      Software industry rating raised to Attractive from In-Line at Morgan Stanley
      03/03/21 Citi
      Atlassian assumed with a Buy at Citi
      01/29/21 DA Davidson
      Atlassian price target raised to $275 from $235 at DA Davidson
      01/29/21 BMO Capital
      Atlassian price target raised to $260 from $235 at BMO Capital
      PKI PerkinElmer
      $135.39 /

      +2.695 (+2.03%)

      02/03/21 Citi
      PerkinElmer price target raised to $155 from $150 at Citi
      01/07/21 Piper Sandler
      Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
      01/07/21 Wells Fargo
      PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
      01/07/21 Wells Fargo
      PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
      MRNA Moderna
      $149.63 /

      +10.34 (+7.42%)

      04/13/21 Morgan Stanley
      Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
      04/13/21 Piper Sandler
      Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
      04/07/21 Jefferies
      Catalent pact with Moderna removes potential overhang, says Jefferies
      03/15/21 Piper Sandler
      Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
      SEAC SeaChange
      $1.38 /

      -0.095 (-6.46%)

      09/09/20 Lake Street
      SeaChange price target lowered to $2 from $4 at Lake Street
      SFIX Stitch Fix
      $49.46 /

      -1.3 (-2.56%)

      04/05/21 Evercore ISI
      Stitch Fix initiated with an Outperform at Evercore ISI
      03/09/21
      Fly Intel: Top five analyst downgrades
      03/09/21 Canaccord
      Stitch Fix price target lowered to $68 from $72 at Canaccord
      03/09/21 KeyBanc
      Stitch Fix price target lowered to $75 from $95 at KeyBanc
      STSA Satsuma Pharmaceuticals
      $5.44 /

      +0.37 (+7.30%)

      04/05/21 Mizuho
      Satsuma Pharmaceuticals price target raised to $7 from $3.50 at Mizuho
      03/02/21 Credit Suisse
      Satsuma Pharmaceuticals upgraded to Neutral from Underperform at Credit Suisse
      03/02/21 Credit Suisse
      Satsuma upgraded to Neutral from Underperform at Credit Suisse
      11/11/20 Mizuho
      Satsuma Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
      TEAM Atlassian
      $242.24 /

      +11.72 (+5.08%)

      STSA Satsuma Pharmaceuticals
      $5.44 /

      +0.37 (+7.30%)

      SFIX Stitch Fix
      $49.46 /

      -1.3 (-2.56%)

      SEAC SeaChange
      $1.38 /

      -0.095 (-6.46%)

      SAP SAP
      $134.51 /

      +2.08 (+1.57%)

      PKI PerkinElmer
      $135.39 /

      +2.695 (+2.03%)

      MRNA Moderna
      $149.63 /

      +10.34 (+7.42%)

      FLXN Flexion
      $9.37 /

      +1.05 (+12.62%)

      BRKR Bruker
      $68.97 /

      +1.43 (+2.12%)

      • 30
        Mar
      • 21
        Oct
      • 21
        May
      • 19
        May
      SAP SAP
      $134.51 /

      +2.08 (+1.57%)

      MRNA Moderna
      $149.63 /

      +10.34 (+7.42%)

      TEAM Atlassian
      $242.24 /

      +11.72 (+5.08%)

      SFIX Stitch Fix
      $49.46 /

      -1.3 (-2.56%)

      SEAC SeaChange
      $1.38 /

      -0.095 (-6.46%)

      SAP SAP
      $134.51 /

      +2.08 (+1.57%)

      PKI PerkinElmer
      $135.39 /

      +2.695 (+2.03%)

      MRNA Moderna
      $149.63 /

      +10.34 (+7.42%)

      BRKR Bruker
      $68.97 /

      +1.43 (+2.12%)

      TEAM Atlassian
      $242.24 /

      +11.72 (+5.08%)

      STSA Satsuma Pharmaceuticals
      $5.44 /

      +0.37 (+7.30%)

      SFIX Stitch Fix
      $49.46 /

      -1.3 (-2.56%)

      SEAC SeaChange
      $1.38 /

      -0.095 (-6.46%)

      SAP SAP
      $134.51 /

      +2.08 (+1.57%)

      MRNA Moderna
      $149.63 /

      +10.34 (+7.42%)

      Get Full Fly Access

      Breaking market intelligence sent straight to you
      Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
      Up-to-date information on important industry events
      Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
      News focused on the companies in your portfolio
      Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.